Table 1 Immunohistochemical antibodies and staining protocol.

From: NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker

Antibody

Manufacturer

Clone

Concentration

Pretreatment

Incubation time /detection

BCOR

Santa Cruz

Sc-514576

C-10

1/50

CC2 (56′)

60′/OptiView universal DAB

CD99,MIC2

Dako, Glostrup, Danemark (M3601)

12E7

1/100

CC1 short (36′)

32′/UltraView universal DAB

Pan-Keratin

Roche Diagnostics (760-2595)

(AE1/AE3/PCK26)

Prediluted

CC1 short (36′) + 

Protéase3(4′)

8′/UltraView universal DAB

Desmin

Roche Diagnostics (760-2513)

DE-R-11

Prediluted

CC1 short (36′)

32′/ UltraView universal DAB

ERG

Dako, Glostrup, Danemark (M7314)

EP111

1/100

CC1 short (36′)

32′/ UltraView universal DAB

PEA3-ETV4

Santa Cruz

Sc-113

16

1/25

CC1 standard (64′)

32′/OptiView universal DAB

 + amplification (8’)

PS100

Dako, Glostrup, Danemark (Z 311)

Rabbit polyclonal

1/2000

CC1 (20′)

32′/UltraView universal DAB

WT1-cTer

Zytomed Systems GmbH

14163 Berlin, Germany (523-3994)

Rabbit polyclonal

1/100

CC1 standard (64′)

32′/UltraView universal DAB

NKX3-1

Bio SB

93111 Santa Barbara, CA, USA

EP356 (CE/IVD)

Rabbit monoclonal

Prediluted

CC1 (48 min)

36′/OptiView universal DAB

AGGRECAN

Abcam (ab186414)

EPR14664

1/1000

CC1 standard (64′)

52′/UltraView universal DAB